Balchem Corporation announced that it completed its acquisition of Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway. The signing of a definitive agreement to acquire Kappa Bioscience AS was previously announced on June 14, 2022.
Join Ted Harris, Chairman of the Board, President, and CEO and Martin Bengtsson, CFO on Friday, July 26, 2024, at 11:00 AM Eastern Time (ET) to review 2nd Quarter 2024 financial results.
Ted Harris, Chairman, President and CEO said, "We delivered solid second quarter financials with record earnings from operations and adjusted EBITDA. I am particularly pleased with the excellent performance in our Human Nutrition and Health and Specialty Products segments, both delivering strong sales and earnings growth."
×
You are leaving the Balchem Corporation website and linking to a non-affiliated third-party site.
